Elastin degradation: An effective biomarker in COPD

COPD: Journal of Chronic Obstructive Pulmonary Disease

Volumn 9, Issue 4, 2012, Pages 435-438

  Turino, Gerard M ^a   Lin, Yong Y ^a   He, Jiangtao ^a   Cantor, Jerome O ^b   Ma, Shuren ^a  

^a ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

^b ST JOHN'S UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

[(3 BENZOYL 1 PYRIDINIOMETHYL) (2 HYDROXYIMINOMETHYL 1 PYRIDINIOMETHYL)] ETHER; BIOLOGICAL MARKER; DESMOSINE; ELASTIN; ISODESMOSINE;

ALPHA 1 ANTITRYPSIN DEFICIENCY; AMINO ACID BLOOD LEVEL; AMINO ACID URINE LEVEL; ARTICLE; CAPILLARY ELECTROPHORESIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; PROTEIN LOCALIZATION;

BIOLOGICAL MARKERS; BRONCHODILATOR AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DESMOSINE; DISEASE PROGRESSION; DRUG MONITORING; ELASTIN; HUMANS; ISODESMOSINE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SEVERITY OF ILLNESS INDEX; TANDEM MASS SPECTROMETRY;

EID: 84865199140     PISSN: 15412555     EISSN: 15412563     Source Type: Journal    
DOI: 10.3109/15412555.2012.697753     Document Type: Article

References (36)

1. Mannino DM, Buist AS. Global burden of COPD: Risk factors, prevalence and future trends. Lancet 2007; 370:765-773.
2. Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. GOLD executive summary. AJRCCM 2007; 176:532-555.
3. Minino, AM, Xu, J, Kochanek, MA. Deaths: Preliminary Data for 2008. National Vital Statistics Reports 2010; 59:1-32.
4. DrugDevelopmentTools Qualifi cationProgram/ucm284076. htm.
5. DeGruttola VG, Clax P, DeMets DL, Downing GJ, Ellenbert SS, Friedman L, Gail MH, Prentice R, Wittes J, Zeger SL. Considerations in the evaluation of surrogate endpoints in clinical trials. Summary of a National Institutes of Health workshop. Contr Clin Trials 2001; 22:485-502.
6. Bucher HC, Guyatt GH, Cook DJ, Holbrook A, McAlister FA. Users guides to the medical literature: XIX. Applying clinical trial results. A. How to use an article measuring the eff ect of an intervention on surrogate end points: evidence-based medicine working group. JAMA 1999; 282:771-778.
7. U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). Guidance for industry chronic obstructive pulmonary disease: Developing drugs for treatment. 2007 [accessed April 14, 2009]. Available from: CDER/GUIDANCE/7875dft.pdf.
8. Mecham RP. Elastin fi bers in the lung. In Crystal RG, West JB, Weibel ER, Barnes PJ eds: Scientifi c Foundations 1997, Philadelphia, Lippincott-Raven, 729-736.
9. Sandberg LB, Soskel NT, Leslie JG. Elastin structure, biosynthesis, and relation to disease states. NEJM 1981; 304(10):566-579.
10. Kuhn C III, Oldmixon EH. Th e interstitium of the lung. In: Schraufnagel DE, ed. Electron Microscopy of the Lung. New York: Marcel Dekker, 1990: 177-214.
11. Wright RR. Elastic tissue of normal and emphysematous lungs - a tridimensional histologic study. Am J Path 1961; 39:355-367.
12. Ma S, Lieberman S, Turino GM, Lin YY. Th e detection and quantitation of free desmosine and isodesmosine in human urine and their peptide-bound forms in sputum: Proc Natl Acad Sci USA 2003; 100:12941-12943.
13. Laurell C-B, Eriksson S. Th e electrophoretic alpha-1-globulin pattern of serum in alpha-1-antitrypsin defi ciency. Scand J Clin Lab Invest 1963; 15:132-140.
14. Brantly MS, Paul LD, Miller BH, Falk RT, Wu M, Crystal RG. Clinical features and history of the destructive lung disease associated with alpha-1-antitrypsin defi ciency of adults with pulmonary symptoms. Am Rev Respir Dis 1988; 138:327-336.
15. Owen CA. Roles for proteinases in the pathogenesis of chronic obstructive pulmonary disease. Internat J COPD 2008; 3(2):253-268.
16. Abboud RT, Fera T, Richter A, et al. Acute eff ect of smoking on the functional activity of alpha1-protease inhibitor in bronchoalveolar lavage fl uid. ARRD 1985; 131:79-85.
17. Darnule TV, McKee M, Darnule AT, Turino GM, Mandl I. Solid-phase radioimmunoassay for estimation of elastin peptides in human sera. Anal Biochem 1982; 122:302-307.
18. Goldstein RA, Starcher BC. Urinary excretion of elastin peptides containing desmosine after intratracheal injection of elastin in hamsters. J Clin Invest 1978; 61:1286-1290.
19. Luisetti M, Ma S, Iadarola P, Stone PJ, Viglio S, Casado B, Lin YY, Snider GL, Turino GM. Desmosine as a biomarker of elastin degradation in COPD: Current status and future directions. ERJ 2008; 32(5):1146-1157.
20. Starcher BC. Antibodies to elastin. Meth Enzymol 1982; 82:759-762.
21. Kucich U, Christner P, Lippmann M, et al. Utilization of a peroxidase antiperoxidase complex in an enzyme-linker immunosorbent assay of elastin-derived peptides in human plasma. Am Rev Respir Dis 1985; 131:709-713.
22. Watanabe T, Ishimori K, Verplanke AJ, Matsuki H, Kasuga H. An enzyme-linked immunosorbena assay (ELISA) for the quantitation of urinary desmosine. Tokai J Exp Clin Med 1989; 14:347-356.
23. Stone PJ, Bryan-Rhafdi H, Lucey EC, et al. Measurement of urinary desmosine by isotope dilution and high performance liquid chromatography. Correlation between elastase-induced air-sace enlargement in the hamster and elevation of urinary desmosine. Am Rev Respir Dis 1991; 144:284-290.
24. Harel S, Janoff A, Yu SY, Hurewitz A, Bergofsky Eh. Desmosine radioimmunoassay for measuring elastin degradation in vivo. Am Rev Respir Dis 1980; 122:769-773.
25. Stone PJ, Gottlieb DJ, OConnor GT, et al. Elastin and collagen degradation products in urine of smokers with and without chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995; 151:952-959.
26. Gottlieb DJ, Stone PJ, Sparrow D, et al. Urinary desmosine excretion in smokers with and without rapid decline of lung function: the Normative Aging Study. AJRCCM 1996; 154:1290-1295.
27. Viglio S, Iadarola P, Lupi A, et al. MEKC of desmosine and isodesmosine in urine of chronic destructive lung disease patients. Eur Respir J 2000; 15:1039-1045.
28. Ma S, Lin YY, Turino GM. Measurement of desmosine and isodesmosine by mass spectrometry in COPD. Chest 2007, 131:1363-1371.
29. Rodriguez JR, Seals JE, Radin A, Lin JS, MandlI, Turino GM. Neutrophil lysosomal elastase activity in normal subjects and in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis 1979; 119:409-417.
30. Ma S, Turino GM, Lin YY. Quantitation of desmosine and isodesmosine in urine, plasma, and sputum by LLC-MS/MS as biomarkers for elastin degradation. J Chromatogr B 2011; 879:1893-1898.
31. Albarbarawi O, Barton A, Lin Z, et al. Measurement of urinary total desmosine and isodesnosine using isotope-dilution liquid chromatography-tandem mass spectrometry. Anal Chem 2010; 82(9):2745-2750.
32. Ma S, Lin YY, Turino GM. Th e eff ect of Tiotropium (TIO) on levels of desmosine and isodesmosine (D/I) in urine, plasma and sputum in COPD. Respir-Res 2009; 12:10.
33. Pera T, Zuidhof A, Valadas J, Smit M, Schoemaker RG, Gosens R, Maaringh H, Zaagsma J, Meurs H. Tiotropium inhibits pulmonary infl ammation and remodeling in a guinea pig model of COPD. EUR Respir J 2011; Feb 24, 2011 (Epub ahead of print, US National Library of Medicine, NIH, PubMed).
34. Cantor JO, Cerreta JM, Ochoa M, Ma S, Liu M, Turino GM. Th erapeutic eff ects of hyaluronan on smoke-induced elastic fi ber injury: Does delayed treatment aff ect effi cacy? Lung 2011; 189:51-56.
35. Fregonese L, Ferrari F, Funagalli M, Luisetti M, Stolk J, Iadarola P. Long-term variability of desmosine/isodesmosine as biomarker in alpha-1-antitrypsin defi ciency-related COPD. J COPD 2011; 3:229-333.
36. Lindberg CA, Engstrom G, Gerhardsson de Verdier M, Nihlen U, Anderson M, Forsman-Semb K, Svartengren M. Total desmosine in plasma and urine correlate with lung function. ERJ 2012; 29:839-845.